Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zeria Of Japan To Buy Tilotts Of Switzerland For $128 Million

This article was originally published in PharmAsia News

Executive Summary

Japan's Zeria Pharma said it plans to buy Tilotts Pharma of Switzerland for just over $128 million. Zeria reportedly made the purchase to expand its drug pipeline and widen its marketing ability abroad. Tilotts is attractive to Zeria because of its Asacol (mesalamine) drug for treating hypersensitive bowel syndrome. The product is considered a good fit with Zeria's gastrointestinal line of drugs. Zeria has been developing and marketing Asacol in Japan for the past five years. The purchase of Tilotts gives the Japanese company rights to sell the drug in 53 countries. (Click here for more - a subscription may be required

You may also be interested in...

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts